{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T17:35:21Z","timestamp":1787160921244,"version":"build-2736575974"},"reference-count":111,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:00:00Z","timestamp":1760486400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:p>Atherosclerosis is a chronic vascular disorder characterized by the pathological accumulation of lipids, inflammatory cells, and extracellular matrix within arterial walls. With the escalating global incidence of atherosclerosis, the development of more effective therapeutic interventions has emerged as a critical priority in biomedical research. Conventional treatment modalities, encompassing pharmacological agents and, endovascular interventions, have demonstrated partial efficacy in disease management. However, their clinical utility remains constrained by suboptimal therapeutic outcomes, treatment-related adverse effects, and instances of therapeutic failure. In response to these limitations, contemporary research has shifted focus toward novel therapeutic strategies targeting molecular pathways and immunomodulatory mechanisms, aiming to achieve enhanced precision and efficacy. This review synthesizes recent innovations in atherosclerosis therapeutics. Notable advancements include PCSK9 inhibitors and next-generation lipid-modulating agents, which have shown significant promise in clinical trials by achieving substantial reductions in atherogenic lipoprotein levels. Gene-editing technologies, particularly CRISPR-based approaches, exhibit potential for halting disease progression through targeted modulation of pro-atherogenic genes. Furthermore, emerging insights into the regulatory role of microRNAs in atherosclerotic plaque formation and instability have positioned miRNA-based therapeutics as a compelling frontier in precision medicine for cardiovascular diseases.<\/jats:p>","DOI":"10.3389\/fcvm.2025.1652933","type":"journal-article","created":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T13:05:43Z","timestamp":1760533543000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Innovative molecular intervention and precision therapy for atherosclerosis"],"prefix":"10.3389","volume":"12","author":[{"given":"Zhijie","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linsheng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feifeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"C7","DOI":"10.1016\/j.jacc.2005.09.068","article-title":"Pathogenesis of atherosclerosis","volume":"47","author":"Falk","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1007\/s11883-018-0711-4","article-title":"Cardiorespiratory fitness and cardiovascular disease prevention: an update","volume":"20","author":"Al-Mallah","year":"2018","journal-title":"Curr Atheroscler Rep"},{"key":"B3","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/1741-7015-11-117","article-title":"Immunity, atherosclerosis and cardiovascular disease","volume":"11","author":"Frosteg\u00e5rd","year":"2013","journal-title":"BMC Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1161\/CIRCRESAHA.118.313591","article-title":"Immunity and inflammation in atherosclerosis","volume":"124","author":"Wolf","year":"2019","journal-title":"Circ Res"},{"key":"B5","doi-asserted-by":"publisher","first-page":"107368","DOI":"10.1016\/j.vph.2024.107368","article-title":"Elucidating the crosstalk between endothelial-to-mesenchymal transition (EndoMT) and endothelial autophagy in the pathogenesis of atherosclerosis","volume":"155","author":"Singh","year":"2024","journal-title":"Vascul Pharmacol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"34573","DOI":"10.1074\/jbc.M205059200","article-title":"Macrophage foam cell formation with native low density lipoprotein","volume":"277","author":"Kruth","year":"2002","journal-title":"J Biol Chem"},{"key":"B7","doi-asserted-by":"publisher","first-page":"e3843","DOI":"10.3390\/cells11233843","article-title":"The role of oxidative stress in atherosclerosis","volume":"11","author":"Batty","year":"2022","journal-title":"Cells"},{"key":"B8","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.atherosclerosis.2014.08.041","article-title":"LDL oxidation by platelets propagates platelet activation via an oxidative stress-mediated mechanism","volume":"237","author":"Carnevale","year":"2014","journal-title":"Atherosclerosis"},{"key":"B9","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1038\/nri.2016.63","article-title":"Innate sensing of oxidation-specific epitopes in health and disease","volume":"16","author":"Binder","year":"2016","journal-title":"Nat Rev Immunol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/S0022-2275(20)31170-6","article-title":"Sequestration of aggregated LDL by macrophages studied with freeze-etch electron microscopy","volume":"42","author":"Haberland","year":"2001","journal-title":"J Lipid Res"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1073\/pnas.86.4.1372","article-title":"Low density lipoprotein undergoes oxidative modification in vivo","volume":"86","author":"Palinski","year":"1989","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1039241","DOI":"10.3389\/fimmu.2022.1039241","article-title":"ROS-triggered endothelial cell death mechanisms: focus on pyroptosis, parthanatos, and ferroptosis","volume":"13","author":"Zheng","year":"2022","journal-title":"Front Immunol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1161\/CIRCRESAHA.115.306301","article-title":"Endothelial cell dysfunction and the pathobiology of atherosclerosis","volume":"118","author":"Gimbrone","year":"2016","journal-title":"Circ Res"},{"key":"B14","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1038\/s41569-023-00883-1","article-title":"Flow-induced reprogramming of endothelial cells in atherosclerosis","volume":"20","author":"Tamargo","year":"2023","journal-title":"Nat Rev Cardiol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1007\/s11883-000-0081-5","article-title":"The good smooth muscle cells in atherosclerosis","volume":"2","author":"Schwartz","year":"2000","journal-title":"Curr Atheroscler Rep"},{"key":"B16","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.phrs.2014.03.002","article-title":"The pharmacology of statins","volume":"88","author":"Sirtori","year":"2014","journal-title":"Pharmacol Res"},{"key":"B17","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/S1734-1140(11)70601-6","article-title":"Statin-induced myopathies","volume":"63","author":"Tomaszewski","year":"2011","journal-title":"Pharmacol Rep"},{"key":"B18","doi-asserted-by":"publisher","first-page":"191","DOI":"10.2147\/cpaa.s288831","article-title":"Safety and tolerability of PCSK9 inhibitors: current insights","volume":"12","author":"Kosmas","year":"2020","journal-title":"Clin Pharmacol Adv Appl"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.7164\/antibiotics.29.1346","article-title":"ML-236A, ML-236B, and ML-236C, new inhibitors of cholesterogenesis produced by penicillium citrinium","volume":"29","author":"Endo","year":"1976","journal-title":"J Antibiot (Tokyo)"},{"key":"B20","first-page":"70","article-title":"Inhibition of in vitro cholesterol synthesis by fatty acids","volume":"486","author":"Kuroda","year":"1976","journal-title":"Biochim Biophys Acta"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1301051","DOI":"10.3389\/fimmu.2023.1301051","article-title":"Metabolic changes with the occurrence of atherosclerotic plaques and the effects of statins","volume":"14","author":"Zhao","year":"2023","journal-title":"Front Immunol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1111\/j.2042-7158.2011.01273.x","article-title":"Statins therapy: a review on conventional and novel formulation approaches","volume":"63","author":"Tiwari","year":"2011","journal-title":"J Pharm Pharmacol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1097\/MJT.0000000000000063","article-title":"New and emerging LDL cholesterol-lowering drugs","volume":"22","author":"Kosmas","year":"2015","journal-title":"Am J Ther"},{"key":"B24","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1161\/ATVBAHA.118.311569","article-title":"Nanoparticle therapy for vascular diseases","volume":"39","author":"Flores","year":"2019","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"3065","DOI":"10.1038\/ncomms4065","article-title":"A statin-loaded reconstituted high-density lipoprotein nanoparticle inhibits atherosclerotic plaque inflammation","volume":"5","author":"Duivenvoorden","year":"2014","journal-title":"Nat Commun"},{"key":"B26","doi-asserted-by":"publisher","first-page":"2622","DOI":"10.1038\/s41467-020-16439-7","article-title":"Treatment of atherosclerosis by macrophage-biomimetic nanoparticles via targeted pharmacotherapy and sequestration of proinflammatory cytokines","volume":"11","author":"Gao","year":"2020","journal-title":"Nat Commun"},{"key":"B27","doi-asserted-by":"publisher","first-page":"2921","DOI":"10.1172\/JCI57275","article-title":"Antagonism of miR-33 in mice promotes reverse cholesterol transport and regression of atherosclerosis","volume":"121","author":"Rayner","year":"2011","journal-title":"J Clin Invest"},{"key":"B28","doi-asserted-by":"publisher","first-page":"e2002131","DOI":"10.1002\/adfm.202002131","article-title":"Site-specific MicroRNA-33 antagonism by pH-responsive nanotherapies for treatment of atherosclerosis via regulating cholesterol efflux and adaptive immunity","volume":"30","author":"Li","year":"2020","journal-title":"Adv Funct Mater"},{"key":"B29","doi-asserted-by":"publisher","first-page":"121324","DOI":"10.1016\/j.biomaterials.2021.121324","article-title":"Dual targeted delivery of statins and nucleic acids by chitosan-based nanoparticles for enhanced antiatherosclerotic efficacy","volume":"280","author":"Jiang","year":"2022","journal-title":"Biomaterials"},{"key":"B30","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1038\/s41569-021-00629-x","article-title":"Macrophage-targeted nanomedicine for the diagnosis and treatment of atherosclerosis","volume":"19","author":"Chen","year":"2022","journal-title":"Nat Rev Cardiol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1055\/s-0039-3400247","article-title":"Iron oxide nanoparticles as imaging and therapeutic agents for atherosclerosis","volume":"46","author":"Talev","year":"2020","journal-title":"Semin Thromb Hemost"},{"key":"B32","doi-asserted-by":"publisher","first-page":"6008","DOI":"10.7150\/thno.24365","article-title":"Nanoparticles targeting extra domain B of fibronectin-specific to the atherosclerotic lesion types III, IV, and V-enhance plaque detection and cargo delivery","volume":"8","author":"Yu","year":"2018","journal-title":"Theranostics"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1159\/000492251","article-title":"Multimodality molecular imaging of cardiovascular disease based on nanoprobes","volume":"48","author":"Tu","year":"2018","journal-title":"Cell Physiol Biochem"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1161\/CIRCULATIONAHA.106.655654","article-title":"Comparison of intravascular ultrasound and quantitative coronary angiography for the assessment of coronary artery disease progression","volume":"115","author":"Berry","year":"2007","journal-title":"Circulation"},{"key":"B35","doi-asserted-by":"publisher","first-page":"e810","DOI":"10.3390\/nano8100810","article-title":"Surface modification of magnetic iron oxide nanoparticles","volume":"8","author":"Zhu","year":"2018","journal-title":"Nanomaterials (Basel)"},{"key":"B36","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.7150\/thno.23789","article-title":"Surface impact on nanoparticle-based magnetic resonance imaging contrast agents","volume":"8","author":"Zhang","year":"2018","journal-title":"Theranostics"},{"key":"B37","doi-asserted-by":"publisher","first-page":"e895","DOI":"10.1161\/CIR.0000000000001063","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"key":"B38","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.jacbts.2019.01.011","article-title":"Overcoming barriers to development of novel therapies for cardiovascular disease: insights from the oncology drug development experience","volume":"4","author":"Khakoo","year":"2019","journal-title":"JACC Basic Transl Sci"},{"key":"B39","doi-asserted-by":"publisher","first-page":"e1392073","DOI":"10.3389\/fcvm.2024.1392073","article-title":"Editorial: nucleic acid-based therapies for cardiovascular diseases","volume":"11","author":"Martelli","year":"2024","journal-title":"Front Cardiovasc Med"},{"key":"B40","doi-asserted-by":"publisher","first-page":"108480","DOI":"10.1016\/j.pharmthera.2023.108480","article-title":"Targeting PCSK9 to tackle cardiovascular disease","volume":"249","author":"Hummelgaard","year":"2023","journal-title":"Pharmacol Ther"},{"key":"B41","doi-asserted-by":"publisher","first-page":"48865","DOI":"10.1074\/jbc.M409699200","article-title":"NARC-1\/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol","volume":"279","author":"Benjannet","year":"2004","journal-title":"J Biol Chem"},{"key":"B42","doi-asserted-by":"publisher","first-page":"e5880","DOI":"10.3390\/ijms22115880","article-title":"PCSK9 Biology and its role in atherothrombosis","volume":"22","author":"Barale","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B43","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/S2213-8587(16)30041-9","article-title":"Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the international atherosclerosis society severe familial hypercholesterolemia panel","volume":"4","author":"Santos","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"10773","DOI":"10.1016\/S0021-9258(18)61030-0","article-title":"Three direct repeats and a TATA-like sequence are required for regulated expression of the human low density lipoprotein receptor gene","volume":"262","author":"S\u00fcdhof","year":"1987","journal-title":"J Biol Chem"},{"key":"B45","doi-asserted-by":"publisher","first-page":"2828","DOI":"10.1016\/S0021-9258(17)35862-3","article-title":"Deletion of clustered O-linked carbohydrates does not impair function of low density lipoprotein receptor in transfected fibroblasts","volume":"261","author":"Davis","year":"1986","journal-title":"J Biol Chem"},{"key":"B46","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1146\/annurev-pharmtox-011613-140025","article-title":"Targeting PCSK9 for hypercholesterolemia","volume":"54","author":"Norata","year":"2014","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1093\/hmg\/ddl077","article-title":"Effect of mutations in the PCSK9 gene on the cell surface LDL receptors","volume":"15","author":"Cameron","year":"2006","journal-title":"Hum Mol Genet"},{"key":"B48","doi-asserted-by":"publisher","first-page":"e0125127","DOI":"10.1371\/journal.pone.0125127","article-title":"Common proprotein convertase subtilisin\/kexin type 9 (PCSK9) epitopes mediate multiple routes for internalization and function","volume":"10","author":"DeVay","year":"2015","journal-title":"PLoS One"},{"key":"B49","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.bbrc.2011.02.023","article-title":"Removal of acidic residues of the prodomain of PCSK9 increases its activity towards the LDL receptor","volume":"406","author":"Holla","year":"2011","journal-title":"Biochem Biophys Res Commun"},{"key":"B50","doi-asserted-by":"publisher","first-page":"20502","DOI":"10.1074\/jbc.M701634200","article-title":"Effects of pH and low density lipoprotein (LDL) on PCSK9-dependent LDL receptor regulation","volume":"282","author":"Fisher","year":"2007","journal-title":"J Biol Chem"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1093\/hmg\/ddr578","article-title":"Interaction between the ligand-binding domain of the LDL receptor and the C-terminal domain of PCSK9 is required for PCSK9 to remain bound to the LDL receptor during endosomal acidification","volume":"21","author":"Tveten","year":"2012","journal-title":"Hum Mol Genet"},{"key":"B52","doi-asserted-by":"publisher","first-page":"5464","DOI":"10.1074\/jbc.M110.199042","article-title":"A two-step binding model of PCSK9 interaction with the low density lipoprotein receptor","volume":"286","author":"Yamamoto","year":"2011","journal-title":"J Biol Chem"},{"key":"B53","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1056\/NEJMp1614154","article-title":"Oligonucleotide therapeutics \u2014 a new class of cholesterol-lowering drugs","volume":"376","author":"Khvorova","year":"2017","journal-title":"N Engl J Med"},{"key":"B54","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s40119-020-00163-w","article-title":"What lessons have we learned and what remains to be clarified for PCSK9 inhibitors? A review of FOURIER and ODYSSEY outcomes trials","volume":"9","author":"Furtado","year":"2020","journal-title":"Cardiol Ther"},{"key":"B55","doi-asserted-by":"publisher","first-page":"173114","DOI":"10.1016\/j.ejphar.2020.173114","article-title":"Statins and PCSK9 inhibitors: a new lipid-lowering therapy","volume":"878","author":"Gallego-Colon","year":"2020","journal-title":"Eur J Pharmacol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"e70174","DOI":"10.1002\/hsr2.70174","article-title":"PCSK9 inhibitors: the evolving future","volume":"7","author":"Jeswani","year":"2024","journal-title":"Health Sci Rep"},{"key":"B57","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1161\/CIRCULATIONAHA.122.062132","article-title":"Efficacy and safety of an investigational single-course CRISPR base-editing therapy targeting PCSK9 in nonhuman primate and mouse models","volume":"147","author":"Lee","year":"2023","journal-title":"Circulation"},{"key":"B58","doi-asserted-by":"publisher","first-page":"e74141","DOI":"10.7759\/cureus.74141","article-title":"Innovative mRNA vaccine approaches in targeting atherosclerosis: a new era in cardiovascular therapy","volume":"16","author":"Kumar","year":"2024","journal-title":"Cureus"},{"key":"B59","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1038\/ni.2391","article-title":"Restraint of inflammatory signaling by interdependent strata of negative regulatory pathways","volume":"13","author":"Murray","year":"2012","journal-title":"Nat Immunol"},{"key":"B60","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1126\/science.aan2691","article-title":"Inflammation by way of macrophage metabolism","volume":"356","author":"Kabat","year":"2017","journal-title":"Science"},{"key":"B61","doi-asserted-by":"publisher","first-page":"17721","DOI":"10.1021\/acsnano.3c00958","article-title":"Modulating plaque inflammation via targeted mRNA nanoparticles for the treatment of atherosclerosis","volume":"17","author":"Gao","year":"2023","journal-title":"ACS Nano"},{"key":"B62","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1056\/NEJMoa1316222","article-title":"A 52-week placebo-controlled trial of evolocumab in hyperlipidemia","volume":"370","author":"Blom","year":"2014","journal-title":"N Engl J Med"},{"key":"B63","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/S0140-6736(14)61374-X","article-title":"Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA part B): a randomised, double-blind, placebo-controlled trial","volume":"385","author":"Raal","year":"2015","journal-title":"Lancet"},{"key":"B64","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1016\/j.jacl.2014.09.007","article-title":"Efficacy and safety of alirocumab, a monoclonal antibody to PCSK9, in statin-intolerant patients: design and rationale of ODYSSEY ALTERNATIVE, a randomized phase 3 trial","volume":"8","author":"Moriarty","year":"2014","journal-title":"J Clin Lipidol"},{"key":"B65","doi-asserted-by":"publisher","first-page":"1332147","DOI":"10.3389\/fphar.2024.1332147","article-title":"Drug-drug interactions with oral anticoagulants: information consistency assessment of three commonly used online drug interactions databases in Switzerland","volume":"15","author":"Coumau","year":"2024","journal-title":"Front Pharmacol"},{"key":"B66","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1038\/s41569-021-00549-w","article-title":"Pharmacogenetics to guide cardiovascular drug therapy","volume":"18","author":"Duarte","year":"2021","journal-title":"Nat Rev Cardiol"},{"key":"B67","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/s41387-024-00295-1","article-title":"The association of triglyceride-glucose index with major adverse cardiovascular and cerebrovascular events after acute myocardial infarction: a meta-analysis of cohort studies","volume":"14","author":"Liu","year":"2024","journal-title":"Nutr Diabetes"},{"key":"B68","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.amjmed.2020.12.008","article-title":"Assessing the impact of comprehensive medication management on achievement of the quadruple aim","volume":"134","author":"McFarland","year":"2021","journal-title":"Am J Med"},{"key":"B69","doi-asserted-by":"publisher","first-page":"113957","DOI":"10.1016\/j.biopha.2022.113957","article-title":"Safety of PCSK9 inhibitors","volume":"156","author":"Grze\u015bk","year":"2022","journal-title":"Biomed Pharmacother"},{"key":"B70","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1080\/13543784.2023.2267972","article-title":"MK-0616: an oral PCSK9 inhibitor for hypercholesterolemia treatment","volume":"32","author":"Burnett","year":"2023","journal-title":"Expert Opin Investig Drugs"},{"key":"B71","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1161\/CIRCULATIONAHA.122.063372","article-title":"Orally bioavailable macrocyclic peptide that inhibits binding of PCSK9 to the low density lipoprotein receptor","volume":"148","author":"Johns","year":"2023","journal-title":"Circulation"},{"key":"B72","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1161\/ATVBAHA.119.312131","article-title":"Smooth muscle cell phenotypic diversity","volume":"39","author":"Liu","year":"2019","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"B73","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.mam.2017.11.007","article-title":"The PDGF\/PDGFR pathway as a drug target","volume":"62","author":"Papadopoulos","year":"2018","journal-title":"Mol Aspects Med"},{"key":"B74","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1111\/j.1365-2362.2009.02095.x","article-title":"PDGF-C and -D and their receptors PDGFR-alpha and PDGFR-beta in atherosclerotic human arteries","volume":"39","author":"Karvinen","year":"2009","journal-title":"Eur J Clin Invest"},{"key":"B75","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.cytogfr.2004.03.004","article-title":"PDGF and cardiovascular disease","volume":"15","author":"Raines","year":"2004","journal-title":"Cytokine Growth Factor Rev"},{"key":"B76","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1161\/01.ATV.0000201070.71787.b8","article-title":"Counter-regulatory function of protein tyrosine phosphatase 1B in platelet-derived growth factor- or fibroblast growth factor-induced motility and proliferation of cultured smooth muscle cells and in neointima formation","volume":"26","author":"Chang","year":"2006","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"B77","doi-asserted-by":"publisher","first-page":"2691","DOI":"10.1021\/bi0265574","article-title":"Identification of protein tyrosine phosphatases associating with the PDGF receptor","volume":"42","author":"Markova","year":"2003","journal-title":"Biochemistry"},{"key":"B78","doi-asserted-by":"publisher","first-page":"7770","DOI":"10.1038\/ncomms8770","article-title":"PDGFR\u03b2 signalling regulates local inflammation and synergizes with hypercholesterolaemia to promote atherosclerosis","volume":"6","author":"He","year":"2015","journal-title":"Nat Commun"},{"key":"B79","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1006\/bbrc.2001.6007","article-title":"Low M(r) protein tyrosine phosphatase inhibits growth and migration of vascular smooth muscle cells induced by platelet-derived growth factor","volume":"289","author":"Shimizu","year":"2001","journal-title":"Biochem Biophys Res Commun"},{"key":"B80","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/j.molmet.2017.06.003","article-title":"Myeloid protein tyrosine phosphatase 1B (PTP1B) deficiency protects against atherosclerotic plaque formation in the ApoE(-\/-) mouse model of atherosclerosis with alterations in IL10\/AMPK\u03b1 pathway","volume":"6","author":"Thompson","year":"2017","journal-title":"Mol Metab"},{"key":"B81","doi-asserted-by":"publisher","first-page":"4464","DOI":"10.1111\/bph.15195","article-title":"Antidiabetic activity in vitro and in vivo of BDB, a selective inhibitor of protein tyrosine phosphatase 1B, from rhodomela confervoides","volume":"177","author":"Luo","year":"2020","journal-title":"Br J Pharmacol"},{"key":"B82","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.ijbiomac.2021.08.091","article-title":"PTP1B inhibition studies of biological active phloroglucinols from the rhizomes of Dryopteris crassirhizoma: kinetic properties and molecular docking simulation","volume":"188","author":"Phong","year":"2021","journal-title":"Int J Biol Macromol"},{"key":"B83","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1074\/jbc.C117.819110","article-title":"A potent, selective, and orally bioavailable inhibitor of the protein-tyrosine phosphatase PTP1B improves insulin and leptin signaling in animal models","volume":"293","author":"Krishnan","year":"2018","journal-title":"J Biol Chem"},{"key":"B84","doi-asserted-by":"publisher","first-page":"7027","DOI":"10.3390\/ijms23137027","article-title":"Human protein tyrosine phosphatase 1B (PTP1B): from structure to clinical inhibitor perspectives","volume":"23","author":"Liu","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B85","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.12980\/APJTB.4.2014C980","article-title":"Nanotechnology: an effective tool for enhancing bioavailability and bioactivity of phytomedicine","volume":"4","author":"Gunasekaran","year":"2014","journal-title":"Asian Pac J Trop Biomed"},{"key":"B86","doi-asserted-by":"publisher","first-page":"e08645","DOI":"10.1002\/adfm.202108645","article-title":"Convergent protein phosphatase inhibitor design for PTP1B and TCPTP: exchangeable vanadium coordination complexes on graphene quantum dots","volume":"32","author":"Feng","year":"2021","journal-title":"Adv Funct Mater"},{"key":"B87","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1126\/science.1225829","article-title":"A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity","volume":"337","author":"Jinek","year":"2012","journal-title":"Science"},{"key":"B88","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1038\/s41467-022-29343-z","article-title":"CRISPR-mediated multiplexed live cell imaging of nonrepetitive genomic loci with one guide RNA per locus","volume":"13","author":"Clow","year":"2022","journal-title":"Nat Commun"},{"key":"B89","doi-asserted-by":"publisher","first-page":"e131","DOI":"10.3390\/cells14020131","article-title":"CRISPR-Cas9 in cardiovascular medicine: unlocking new potential for treatment","volume":"14","author":"Bonowicz","year":"2025","journal-title":"Cells"},{"key":"B90","doi-asserted-by":"publisher","first-page":"e40913","DOI":"10.1371\/journal.pone.0040913","article-title":"Cleavage of phage DNA by the Streptococcus thermophilus CRISPR3-cas system","volume":"7","author":"Magad\u00e1n","year":"2012","journal-title":"PLoS One"},{"key":"B91","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1161\/CIRCULATIONAHA.119.042476","article-title":"In vivo AAV-CRISPR\/Cas9-mediated gene editing ameliorates atherosclerosis in familial hypercholesterolemia","volume":"141","author":"Zhao","year":"2020","journal-title":"Circulation"},{"key":"B92","doi-asserted-by":"publisher","first-page":"3949","DOI":"10.1093\/eurheartj\/ehaa140","article-title":"The haemochromatosis gene Hfe and Kupffer cells control LDL cholesterol homeostasis and impact on atherosclerosis development","volume":"41","author":"Demetz","year":"2020","journal-title":"Eur Heart J"},{"key":"B93","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.atherosclerosis.2019.02.012","article-title":"Regulation of MFGE8 by the intergenic coronary artery disease locus on 15q26.1","volume":"284","author":"Soubeyrand","year":"2019","journal-title":"Atherosclerosis"},{"key":"B94","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.1038\/s41467-018-04048-4","article-title":"RNA-guided transcriptional silencing in vivo with S. aureus CRISPR-Cas9 repressors","volume":"9","author":"Thakore","year":"2018","journal-title":"Nat Commun"},{"key":"B95","doi-asserted-by":"publisher","first-page":"13735","DOI":"10.1074\/jbc.M807899200","article-title":"Identification of a new functional domain in angiopoietin-like 3 (ANGPTL3) and angiopoietin-like 4 (ANGPTL4) involved in binding and inhibition of lipoprotein lipase (LPL)","volume":"284","author":"Lee","year":"2009","journal-title":"J Biol Chem"},{"key":"B96","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.atherosclerosis.2017.08.031","article-title":"Role of angiopoietin-like 3 (ANGPTL3) in regulating plasma level of low-density lipoprotein cholesterol","volume":"268","author":"Xu","year":"2018","journal-title":"Atherosclerosis"},{"key":"B97","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1161\/CIRCULATIONAHA.117.031335","article-title":"Reduced blood lipid levels with in vivo CRISPR-Cas9 base editing of ANGPTL3","volume":"137","author":"Chadwick","year":"2018","journal-title":"Circulation"},{"key":"B98","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1186\/s13287-020-01728-1","article-title":"The involving progress of MSCs based therapy in atherosclerosis","volume":"11","author":"Lin","year":"2020","journal-title":"Stem Cell Res Ther"},{"key":"B99","doi-asserted-by":"publisher","first-page":"285","DOI":"10.18632\/aging.101735","article-title":"MSC\u2014targets for atherosclerosis therapy","volume":"11","author":"Colmegna","year":"2018","journal-title":"Aging (Albany NY)"},{"key":"B100","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.arr.2010.08.005","article-title":"MSCs: biological characteristics, clinical applications and their outstanding concerns","volume":"10","author":"Si","year":"2011","journal-title":"Ageing Res Rev"},{"key":"B101","doi-asserted-by":"publisher","first-page":"3900","DOI":"10.18632\/aging.102009","article-title":"Mesenchymal stem cells rejuvenate cardiac muscle through regulating macrophage polarization","volume":"11","author":"Zhang","year":"2019","journal-title":"Aging (Albany NY)"},{"key":"B102","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1093\/cvr\/cvy271","article-title":"Humoral factors secreted from adipose tissue-derived mesenchymal stem cells ameliorate atherosclerosis in ldlr-\/- mice","volume":"115","author":"Takafuji","year":"2019","journal-title":"Cardiovasc Res"},{"key":"B103","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s11010-014-2272-3","article-title":"Mesenchymal stem cells alleviate atherosclerosis by elevating number and function of CD4(+)CD25 (+)FOXP3 (+) regulatory T-cells and inhibiting macrophage foam cell formation","volume":"400","author":"Wang","year":"2015","journal-title":"Mol Cell Biochem"},{"key":"B104","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1089\/scd.2016.0349","article-title":"Effect of the microenvironment on mesenchymal stem cell paracrine signaling: opportunities to engineer the therapeutic effect","volume":"26","author":"Kusuma","year":"2017","journal-title":"Stem Cells Dev"},{"key":"B105","doi-asserted-by":"publisher","first-page":"8472","DOI":"10.1038\/ncomms9472","article-title":"Mesenchymal stem cells use extracellular vesicles to outsource mitophagy and shuttle microRNAs","volume":"6","author":"Phinney","year":"2015","journal-title":"Nat Commun"},{"key":"B106","doi-asserted-by":"publisher","first-page":"146","DOI":"10.3389\/fbioe.2020.00146","article-title":"Extracellular vesicles derived from mesenchymal stem cells (MSC) in regenerative medicine: applications in skin wound healing","volume":"8","author":"Casado-D\u00edaz","year":"2020","journal-title":"Front Bioeng Biotechnol"},{"key":"B107","doi-asserted-by":"publisher","first-page":"44","DOI":"10.5966\/sctm.2014-0091","article-title":"Mesenchymal stem cells ameliorate atherosclerotic lesions via restoring endothelial function","volume":"4","author":"Lin","year":"2015","journal-title":"Stem Cells Transl Med"},{"key":"B108","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1186\/s13287-017-0640-0","article-title":"Mesenchymal stromal cells ameliorate oxidative stress-induced islet endothelium apoptosis and functional impairment via Wnt4-\u03b2-catenin signaling","volume":"8","author":"Wang","year":"2017","journal-title":"Stem Cell Res Ther"},{"key":"B109","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1093\/cvr\/cvaa118","article-title":"Ex vivo ikk\u03b2 ablation rescues the immunopotency of mesenchymal stromal cells from diabetics with advanced atherosclerosis","volume":"117","author":"Kizilay Mancini","year":"2021","journal-title":"Cardiovasc Res"},{"key":"B110","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1186\/s13287-021-02609-x","article-title":"The safety of MSC therapy over the past 15 years: a meta-analysis","volume":"12","author":"Wang","year":"2021","journal-title":"Stem Cell Res Ther"},{"key":"B111","doi-asserted-by":"publisher","first-page":"e73296","DOI":"10.18632\/oncotarget.20265","article-title":"Tumor-educated mesenchymal stem cells promote pro-metastatic phenotype","volume":"8","author":"Hill","year":"2017","journal-title":"Oncotarget"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2025.1652933\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T13:05:44Z","timestamp":1760533544000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2025.1652933\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,15]]},"references-count":111,"alternative-id":["10.3389\/fcvm.2025.1652933"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2025.1652933","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,15]]},"article-number":"1652933"}}